Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Protalix Biotherapeutics Inc    PLX

PROTALIX BIOTHERAPEUTICS INC (PLX)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 12/13 04:24:26 pm
151 ILa   -3.51%
05/04PROTALIX BIOTHERAPEUTICS INC : quaterly earnings release
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Tel Aviv Stock Exchange
12/09/2018 12/10/2018 12/11/2018 12/12/2018 12/13/2018 Date
158.1(c) 159.5(c) 157.8(c) 156.5(c) 154(c) Last
222 889 61 551 167 750 213 190 50 637 Volume
-1.98% +0.89% -1.07% -0.82% -1.60% Change
More quotes
Financials (USD)
Sales 2013 15,8 M
EBIT 2013 -19,9 M
Net income 2013 -19,0 M
Debt 2013 -
Yield 2013 -
Sales 2014 35,8 M
EBIT 2014 -12,9 M
Net income 2014 -4,70 M
Debt 2014 -
Yield 2014 -
P/E ratio 2013 -
P/E ratio 2014
Capi. / Sales2013 3,78x
Capi. / Sales2014 1,66x
Capitalization 59,5 M
More Financials
Company
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name... 
Sector
Biotechnology & Medical Research
Calendar
12/13 | 11:00amShareholder meeting
More about the company
Surperformance© ratings of Protalix Biotherapeutics I
Trading Rating : Investor Rating :
More Ratings
Latest news on PROTALIX BIOTHERAPEUTICS I
12/13PROTALIX BIOTHERAPEUTICS, INC. : Submission of Matters to a Vote of Security Hol..
AQ
11/07PROTALIX : 3Q Earnings Snapshot
AQ
11/07PROTALIX BIOTHERAPEUTICS, INC. : Results of Operations and Financial Condition (..
AQ
11/07Protalix BioTherapeutics Reports 2018 Third Quarter Results and Provides Corp..
GL
10/29Protalix BioTherapeutics to Hold Third Quarter 2018 Financial Results and Cor..
GL
10/10PROTALIX BIOTHERAPEUTICS : Presents Positive Preliminary Data from the BRIDGE St..
AQ
10/06PROTALIX BIOTHERAPEUTICS : Presents Positive Preliminary Data from the BRIDGE St..
AQ
10/06PROTALIX BIOTHERAPEUTICS : Presents Positive Preliminary Data from the BRIDGE St..
AQ
10/05PROTALIX BIOTHERAPEUTICS, INC. : Regulation FD Disclosure (form 8-K)
AQ
10/05PROTALIX BIOTHERAPEUTICS : Presents Positive Preliminary Data from the BRIDGE St..
AQ
More news
Analyst Recommendations on PROTALIX BIOTHERAPEUTICS I
More recommendations
Sector news : Biotechnology & Medical Research - NEC
12/13Lilly, Incyte Get FDA Fast-Track Designation for Baricitinib in Systemic Lupu..
DJ
12/10Almost half of S&P 500 stocks in a bear market
RE
12/10ROCHE : Gilead Sciences snares Roche veteran O'Day as CEO
RE
12/10LONZA : to Establish Biomanufacturing Base in China
DJ
12/10Roche Pharmaceuticals Names New CEO as O'Day Leaves to Head Gilead -- Update
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart PROTALIX BIOTHERAPEUTICS INC
Duration : Period :
Protalix Biotherapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTALIX BIOTHERAPEUTICS I
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 6,50 $
Spread / Average Target 1 504%
EPS Revisions
Managers
NameTitle
Moshe Manor President, Chief Executive Officer & Director
Shlomo Yanai Chairman
Yaron Naos Senior Vice President-Operations
Yossi Maimon CFO, Secretary, Treasurer & Vice President
Yoseph Shaaltiel Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
PROTALIX BIOTHERAPEUTICS INC-32.28%59
IQVIA HOLDINGS INC24.11%24 306
CELLTRION, INC.--.--%24 149
LONZA GROUP16.86%23 031
INCYTE CORPORATION-28.95%14 320
SEATTLE GENETICS, INC.14.02%9 843